BostonGene Announces Acceptance of Seven Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
WALTHAM, MA, May 19, 2020 — BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting. All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.
“We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGene‘s advanced precision medicine capabilities and our commitment to transform the lives of cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.
Details of abstract presentations are as follows:
Abstract Number: 8055*
Title: “Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Krystle Nomie, PhD, BostonGene
Poster: 388
Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.
Research conducted with The University of Texas MD Anderson Cancer Center
Abstract Number: 6561*
Title: “Immune functional portraits of head and neck cancer using next generation sequencing”
Session: Head and Neck Cancer
Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Poster: 222
BostonGene’s comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.
Research conducted with Massachusetts General Hospital
Abstract Number: 8054*
Title: “Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Cody Ramirez at Washington University in St Louis
Poster: 387
Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.
Research conducted with Washington University in St Louis
Abstract Number: e20065
Title: “Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma”
First Author: Krystle Nomie, PhD, BostonGene
Research conducted with The University of Texas MD Anderson Cancer Center
Abstract Number: e21026
Title: “Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies”
First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Research conducted with Massachusetts General Hospital
Abstract Number: e17106
Title: “Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma”
First Author: James Hsieh, MD, PhD at Washington University in St. Louis
Research conducted with Washington University in St Louis
Abstract Number: e17506
Title: “Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome”
First Author: Eric H. Kim, MD at Washington University in St. Louis
Research conducted with Washington University in St Louis
*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020
WALTHAM, MA, May 19, 2020 — BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting. All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.
“We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGene‘s advanced precision medicine capabilities and our commitment to transform the lives of cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.
Details of abstract presentations are as follows:
Abstract Number: 8055*
Title: “Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Krystle Nomie, PhD, BostonGene
Poster: 388
Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.
Research conducted with The University of Texas MD Anderson Cancer Center
Abstract Number: 6561*
Title: “Immune functional portraits of head and neck cancer using next generation sequencing”
Session: Head and Neck Cancer
Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Poster: 222
BostonGene’s comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.
Research conducted with Massachusetts General Hospital
Abstract Number: 8054*
Title: “Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Cody Ramirez at Washington University in St Louis
Poster: 387
Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.
Research conducted with Washington University in St Louis
Abstract Number: e20065
Title: “Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma”
First Author: Krystle Nomie, PhD, BostonGene
Research conducted with The University of Texas MD Anderson Cancer Center
Abstract Number: e21026
Title: “Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies”
First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Research conducted with Massachusetts General Hospital
Abstract Number: e17106
Title: “Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma”
First Author: James Hsieh, MD, PhD at Washington University in St. Louis
Research conducted with Washington University in St Louis
Abstract Number: e17506
Title: “Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome”
First Author: Eric H. Kim, MD at Washington University in St. Louis
Research conducted with Washington University in St Louis
*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
